Lifecore Biomedical (LFCR) Competitors

Arcus Biosciences (NYSE:RCUS) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

Do institutionals & insiders hold more shares of RCUS or LFCR?

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 32.2% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Do analysts rate RCUS or LFCR?

Arcus Biosciences currently has a consensus target price of $21.29, indicating a potential upside of 130.99%. Lifecore Biomedical has a consensus target price of $8.00, indicating a potential upside of 7.96%. Given Arcus Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Arcus Biosciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Lifecore Biomedical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has more volatility and risk, RCUS or LFCR?

Arcus Biosciences has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Does the media favor RCUS or LFCR?

In the previous week, Arcus Biosciences had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for Arcus Biosciences and 3 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.24 beat Arcus Biosciences' score of 0.53 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Lifecore Biomedical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, RCUS or LFCR?

Lifecore Biomedical has lower revenue, but higher earnings than Arcus Biosciences. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$258M	3.78	-$283M	-$4.19	-2.20
Lifecore Biomedical	$130.31M	2.11	$12.01M	-$1.45	-5.11

Is RCUS or LFCR more profitable?

Lifecore Biomedical has a net margin of -35.90% compared to Arcus Biosciences' net margin of -258.94%. Arcus Biosciences' return on equity of -70.58% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-258.94%	-70.58%	-32.97%
Lifecore Biomedical	-35.90%	-551.09%	-13.89%

Summary

Arcus Biosciences beats Lifecore Biomedical on 11 of the 17 factors compared between the two stocks.